| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 8.73 | -0.28 (-3.11%) | 2.55 - 30.00 | 3.6 thousand (Below Avg) |
Market data as of 4:00PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 8.86 |
|---|---|
| Previous Close | 9.01 |
| Day's Range | 8.73 - 9.10 |
| Market Cap | 77.6M |
| Avg Volume (10 Day) | 22.1K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.93 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Imprimis Pharmaceuticals, Inc. Concludes Type C Meeting at the FDA
PR Newswire - Thursday 04/18/2013 8:00 AM ET
| IMMY | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -97.50% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | 31037.77 |
| Company | Last | Change |
|---|---|---|
| 6.75 | -7.66% | |
| Transition Therapeutics Inc | 2.90 | +0.69% |
| Medgenics Inc | 4.25 | -1.62% |
| Prana Biotechnology Ltd | 2.31 | +3.42% |
| Zalicus Inc | 0.60 | -3.23% |
Data is delayed by at least 15 min.